Evaluation of effect of genetic polymorphism on antidiabetic medication in Indian patients with Type 2 Diabetes for development of a pharmacogenomic test for T2DM patients - NI

Chellaram Diabetes Research Centre0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•Subjects from Indian population diagnosed with Type 2 diabetes according to the criteria of the American Diabetes Association.
•Subjects having with HbA1c in the range of 7.5–12% and either on monotherapy or combination therapy on antidiabetic drugs.
•Subjects over 18 years old and below 60 years
•Subjects who agree with the written informed consent to participate in the study

•Other than Indian ethnicity
•Under 18 years old
•Pregnant or lactating women
•Patients with malignancies, and chronic kidney disease stage 3–5, liver cirrhosis
•Presently suffering from congestive heart failure requiring pharmacologic treatment (medical history)
•Past history of urinary or gastric retention or narrow-angle glaucoma
•Presently severe anaemia
•Taking a medication that could confound study results, such as known substrates or inhibitors of OCT3 and MATE1, such as cimetidine.
•They do not provide consent to participate in the study.

发起方

Chellaram Diabetes Research Centre